NCT01422317 - Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

September 30, 1995

Primary Completion Date

December 31, 1997

Study Completion Date

December 31, 2002

Conditions

Coronary DiseaseMyocardial Infarction

Interventions

DRUG

EPA / DHA / Alpha-Tocopherol

Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.

DRUG

Corn Oil / Alpha-Tocopherol (4 mg)

Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol

Trial Locations (1)

4011

Central Hospital in Rogalanad, Stavanger